Inventors
Mohamad Morsey, Yuanzheng Zhang, and Ian Tarpey
Assignees
- Intervet Inc., Madison, NJ
Abstract
The present invention discloses caninized antibodies with specific properties . The present invention also discloses caninized murine antibodies against canine PD – 1 that have a high binding affinity for canine PD – 1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
CovalX Technology Used
Outcomes
Mass spectroscopy was used to identify discontinuous epitopes that may be recognized by anti-canine PD-1. CovalX completed the epitope mapping of canine PD-1. Through this method, researchers were able to identify portions of epitopes that were recognized by mAbs. For example, mAb 3B6 recognizes part of an epitope that is located in the extracellular domain of canine-PD-1. It was also found that caninized antibody 2G9 (R62, R69, R72, and R75) is recognizes the epitope on canine PD-1. R75 is considered to be an important amino acid residue by the researchers because it appeared in multiple epitopes of canine PD-1.
Patent Number
US20190002562A1
US20220204615A1
